Cleveland, S. Matthew, Taylor, H. P. and Dimmock, N. J.. (1997) Selection of neutralizing antibody escape mutants with type A influenza virus HA-specific polyclonal antisera: possible significance for antigenic drift. Epidemiology and Infection, Vol.118 (No.2). pp. 149-154. ISSN 0950-2688

PDF WRAP_Dimmock_neutralizing_antibody.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (189Kb)

Abstract

Ten antisera were produced in rabbits by two or three intravenous injections of inactivated whole influenza type A virions. All contained haemagglutination-inhibition (HI) antibody directed predominantly to an epitope in antigenic site B and, in addition, various amounts of antibodies to an epitope in site A and in site D. The ability of untreated antisera to select neutralization escape mutants was investigated by incubating virus possessing the homologous haemagglutinin with antiserum adjusted to contain anti-B epitope HI titres of 100, 1000 and 10000 HIU/ml. Virus-antiserum mixtures were inoculated into embryonated hen's eggs, and progeny virus examined without further selection. Forty percent of the antisera at a titre of 1000 HIU/ml selected neutralizing antibody escape mutants as defined by their lack of reactivity to Mab HC10 (site B), and unchanged reactivity to other Mabs to site A and site D epitopes. All escape mutant-selecting antisera had a ratio of anti-site B (HC10)-epitope antibody[ratio]other antibodies of [gt-or-equal, slanted]2·0[ratio]1. The antiserum with the highest ratio (7·4[ratio]1) selected escape mutants in all eggs tested in four different experiments. No antiserum used at a titre of 10000 HIU/ml allowed multiplication of any virus. All antisera used at a titre of 100 HIU/ml permitted virus growth, but this was wild-type (wt) virus. We conclude that a predominant epitope-specific antibody response, a titre of [gt-or-equal, slanted]1000 HIU/ml, and a low absolute titre of other antibodies ([less-than-or-eq, slant]500 HIU/ml) are three requirements for the selection of escape mutants. None of the antisera in this study could have selected escape mutants without an appropriate dilution factor, so the occurrence of an escape mutant-selecting antiserum in nature is likely to be a rare event.

Item Type:	Journal Article
Subjects:	Q Science > QR Microbiology > QR355 Virology
Divisions:	Faculty of Science > Life Sciences (2010- ) > Biological Sciences ( -2010)
Library of Congress Subject Headings (LCSH):	Influenza A virus -- Research, Viral antibodies -- Research, Influenza viruses -- Variation, Influenza vaccines -- Research
Journal or Publication Title:	Epidemiology and Infection
Publisher:	Cambridge University Press
ISSN:	0950-2688
Date:	April 1997
Volume:	Vol.118
Number:	No.2
Page Range:	pp. 149-154
Identification Number:	10.1017/S0950268896007303
Status:	Peer Reviewed
Access rights to Published version:	Open Access
Funder:	University of Warwick
References:	1. Kilbourne ED. In¯uenza. New York: Plenum Medical Book Co., 1987. 2. Potter CW. Inactivated in¯uenza virus vaccines. In: Beare AS, ed. Basic and applied in¯uenza research. Boca Raton: CRC Press, 1982: 119±58. 3. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of in¯uenza A viruses. Microbiol Rev 1992; 56: 152±79. 4. Wilson IA, Cox NJ. Structural basis of immune recognition of in¯uenza virus hemagglutinin. Ann Rev Immunol 1990; 8: 737±71. 5. Archetti I, Horsfall FL. Persistent antigenic variation of in¯uenza A viruses after incomplete neutralization in ovo with heterologous immune serum. J Exp Med 1950; 92: 441±62. 6. Isaacs A. The 1951 in¯uenza virus. Proc R Soc Med 1951; 44: 801±3. 7. Laver WG, Webster RG. Selection of antigenic mutants of in¯uenza viruses. Isolation and peptide mapping of their hemagglutinating proteins. Virol 1968; 34: 193±202. 8. Fazekas de St Groth S. Antigenic, adaptive and adsorbtive variants of the in¯uenza A hemagglutinin. In: Laver WG, Bachmayer H, Weil R, eds. Topics in infectious disease. Vol. 3. Vienna: Springer-Verlag, 1978: 25±48. 9. Hyslop NStG. Isolation of variant strains from footand- mouth disease virus propagated in cell cultures containing antiviral serum. J Gen Microbiol 1965; 41: 135±42. 10. Rojas ER, Carillo E, Schiappacassi M, Campos R. Modi®cation of foot-and-mouth disease virus 01 Caseros after serial passages in the presence of antiviral polyclonal sera. J Virol 1992; 66: 3368±72. 11. Reitz MS, Wilson C, Naugle C, Gallo RC, Robert- Guroff M. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 1988; 54: 57±63. 12. McKeating JA, Bennett J, Zolla-Pazner S, et al. Resistance of a human serum-selected human immunode ®ciency virus type 1 to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120. J Virol 1993; 67: 5216±25. 13. Hyslop NStG, Fagg RH. Isolation of variants during passage of a strain of foot-and-mouth disease virus in partly immunized cattle. J Hyg 1965; 63: 357±68. 14. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine escape mutants of hepatitis B virus. Lancet 1990; 336: 325±9. 15. Harrison TJ, Oon CJ, Zuckerman AJ. A novel escape variant (ala 144) of hepatitis B virus in an identical twin before selection in the mother. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral hepatitis and liver disease. Tokyo: Springer-Verlag, 1994: 248±51. 16. Albert J, Abrahamsson B, Nagy K, et al. Rapid development of isolate-speci®c neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990; 4: 107±12. 17. Arendrup M, So$ nnerborg A, Svennerholm B, et al. Neutralizing antibody response during human immunode ®ciency virus type 1 infection : type and group speci®city and viral escape. J Gen Virol 1993; 74: 855±63. 18. Nara PL, Smit L, Dunlop N, et al. Emergence of viruses resistant to neutralization by V3-speci®c antibodies in experimental human immunode®ciency virus type 1 IIIB infection of chimpanzees. J Virol 1990; 64: 3779±91. 19. Watkins BA, Reitz MS, Wilson CA, Aldrich K, Davis AE, Robert-Guroff M. Immune escape by human immunode®ciency virus type 1 from neutralizing antibodies: evidence for multiple pathways. J Virol 1993; 67: 7493±500. 20. Lambkin R, McLain L, Jones SE, Aldridge SL, Dimmock NJ, Neutralization escape mutants of type A in¯uenza virus are readily selected by antiserum from mice immunized with whole virus : a possible mechanism for antigenic drift. J Gen Virol 1994; 75: 3493±502. 21. Lambkin R, Dimmock NJ. All rabbits immunized with type A in¯uenza virions have a serum antibody haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B. J Gen Virol 1995; 76: 889±97. 22. Lambkin R, Dimmock NJ. Longitudinal study of an epitope-biased haemagglutination-inhibition antibody response in rabbits immunized with type A in¯uenza virus. Vaccine 1996; 14: 212±8. 23. Sugrue RJ, Bahadur G, Zambon MC, Hall-Smith M, Douglas AR, Hay AJ. Speci®c structural alteration of the in¯uenza haemagglutinin by amantadine. EMBO J 1990; 9: 3469±76. 24. Wiley DC, Wilson IA, Skehel JJ. Structural identifcication of the antibody-binding sites of Hong Kong in¯uenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289: 373±8. 25. Roberts PC, Garten W, Klenk H-D. Role of conserved glycosylation sites in maturation and transport of in¯uenza A virus hemagglutinin. J Virol 1993; 67: 3048±60. 26. Smith CA, Barnett BC, Thomas DB, Temoltzin- Palacios F. Structural assignments of novelandimmunodominant antigenic sites in the neutralizing antibody response of CBA}Ca mice to in¯uenza virus. J Exp Med 1991; 173: 953±9. 27. Temoltzin-Palacios F, Thomas DB. Modulation of immunodominant sites in in¯uenza hemagglutinin compromise antigenic variation and select receptorbinding variant viruses. J Immunol 1994; 179: 1719±24. 28. Patera AC, Graham CM, Thomas DB, Smith CA. Immunodominance with progenitor B cell diversity in the neutralizing antibody repertoire to in¯uenza infection. Eur J Immunol 1995; 25: 1803±9. 29. Clarke SH, Staudt LM, Kavaler J, Schwartz D, Gerhard WU, Weigert MG. V region gene usage and somatic mutation in the primary and secondary responses to in¯uenza virus hemagglutinin. J Immunol 1990; 144: 2795±801. 30. Haaheim LR. Haemagglutinin-inhibition antibodies in human sera to an antigenic mutant of in¯uenza A}Texas}1}77 (H3N2) virus obtained in vitro. Acta Pathol Microbiol Immunol Scand B 1980; 88: 351±3. 31. Natali A, Oxford JS, Schild GC. Frequency of naturally occurring antibody to in¯uenza virus antigenic variants selected in vitro with monoclonal antibody. J Hyg 1981; 87: 185±90. 32. Oxford JS, Haaheim LR, Slepushkin A, Werner J, Kuwert E, Schild GC. Strain speci®city of serum antibody to the haemagglutinin of in¯uenza A (H3N2) viruses in children following immunization or natural infection. J Hyg 1981; 86: 17±26. 33. Wang M-L, Skehel JJ, Wiley DC. Comparative analyses of the speci®cities of anti-in¯uenza hemagglutinin antibodies in human sera. J Virol 1986; 57: 124±8.
URI:	http://wrap.warwick.ac.uk/id/eprint/3020

Request changes to a record

Actions (login required)

View Item